Interval debulking surgery in advanced epithelial ovarian cancer

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 16, Issue 4, 2002, Pages 573-583

  Pecorelli, Sergio ^a,b,c   Odicino, Franco ^a   Favalli, Giuseppe ^b  

^a UNIVERSITY OF BRESCIA   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c SPEDALI CIVILI   (Italy)

Author keywords

Combined modality therapy; Ovarian neoplasms; Re operation; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; HUMAN; MINIMAL RESIDUAL DISEASE; MORBIDITY; OVARY CANCER; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SURGICAL MORTALITY; FEMALE; MULTIMODALITY CANCER THERAPY; OVARY TUMOR; PATHOLOGY; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; OVARIAN NEOPLASMS; SURVIVAL RATE;

EID: 0036673370     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1053/beog.2002.0302     Document Type: Article

References (34)

1. Griffith CTH. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. National Cancer Institute Monographs 1975; 42: 1010-1014.
2. Hoskins WJ et al. The effect of the diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. American Journal of Obstetrics & Gynecology 1994; 170: 974-980.
3. Piver MS et al. The impact of aggressive debulking surgery and cisplatin based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. Journal of Clinical Oncology 1988; 6: 983-989.
4. Heintz APM et al. The treatment of advanced ovarian carcinoma: clinical variables associated with prognosis. Gynecologic Oncology 1988; 30: 347-358.
5. Hacker NF et al. Primary cytoreductive surgery for epithelial ovarian cancer. Obstetrics & Gynecology 1983; 61: 413-420.
6. De Vita VT. Principles of chemotherapy. In De Vita VT et al (eds) Cancer: Principles and Practice of Oncology, 4th edn, pp 997-. Philadelphia, PA: Lippincott-Raven, 1997.
7. Griffith CT et al. Role of cytoreductive surgical therapy in the management of advanced ovarian cancer. Cancer Treatment Report 1979; 63: 335-340.
8. Covens AL. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecologic Oncology 2000; 78: 269-274.
9. Nejit JP, tenBokkel Huinink WW, van der Burg MEL et al. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. Journal of Clinical Oncology 1987; 5: 1157-1168.
10. Jacob JH, Gersherson DM, Morris M et al. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecologic Oncology 1991; 42: 146-150.
11. Nejit JP, tenBokkel Huinink WW, van der Burg MEL et al. Long-term survival in ovarian cancer: mature data from the Netherland Joint Study Group for Ovarian Cancer. European Journal of Cancer 1991; 27: 1367-1372.
12. Nejit JP, tenBokkel Huinink WW, van den Burg MEL et al. Randomized trial comparing the combination chemotherapy regimens (CHAP-5 vs CP) in advanced ovarian carcinoma. Journal of Clinical Oncology 1987; 5: 1157-1168.
13. Varma R, Redman CWE, Blackledge G et al. Early second surgery in bulky epithelial ovarian cancer does not improve survival: results of a randomized study. Abstract of the 2nd meeting of IGCS, Toronto, October 9-13, 1989.
14. Redman CWE, Warwick J, Luesley DM et al. Intervention debulking surgery in advanced epithelial ovarian cancer. British Journal of Obstetrics and Gynaecology 1994; 101: 142-146.
15. van der Burg MEL, van Lent M, Buyse M et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. New England Journal of Medicine 1995; 332: 629-634.
16. van der Burg MEL et al. After 6 years follow-up intervention debulking surgery remains an independent prognostic factor for survival in advanced epithelial ovarian cancer: an EORTC-GCCG study. International Journal of Gynecological Cancer 1997; 7:.
17. Kehoe S, Shafi M & Luesley D. Interval cytoreduction in ovarian cancer (letter). New England Journal of Medicine 1995; 333: 254.
18. Neijt JP. Interval cytoreduction in ovarian cancer (letter). New England Journal of Medicine 1995; 333: 254-255.
19. Cannistra SA. Interval cytoreduction in ovarian cancer (letter). New England Journal of Medicine 1995; 333: 255.
20. Van der Burg MEL, Buyse M & Pecorelli S. Interval cytoreduction in ovarian cancer (letter). New England Journal of Medicine 1995; 333: 255.
21. Blythe JG & Wahl TP. Debulking surgery: does it increase the quality of survival? Gynecologic Oncology 1982; 14: 396-408.
22. Hacker NF. Cytoreduction for advanced ovarian cancer in perspective. International Journal of Gynecological Cancer 1996; 6: 159-160.
23. Lawton FG et al. Neoadjuvant 'cytoreductive' chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer. Obstetrics & Gynecolology 1989; 73: 61-65.
24. Surwit E et al. Neoadjuvant chemotherapy for advanced ovarian cancer. International Journal of Gynecological Cancer 1996; 6: 356-361.
25. Vergote I, De Wever I, Tjalma W et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecological Oncology 1998; 71: 431-436.
26. Ansquer Y, Leblanc E, Clough K et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma. Cancer 2001; 91: 2329-2334.
27. National Institute of Health Issue Consensus Development Conference Statement: Ovarian Cancer. Screening Treatment and Follow up. Gynecologic Oncology 1993; 4: 83-88.
28. Gore ME, Fryatt B, Wiltshaw & Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecologic Oncology 1990; 36: 207-211.
29. Markman M, Rothman R, Hakes T et al. Second line platinum therapy in patients with ovarian cancer previously treated with cisplatin. Journal of Clinical Oncology 1991; 9: 383-393.
30. Janicke F, Holscher M, Kuhn W et al. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer 1992; 70: 2129-2136.
31. Munkarah AR, Gershenson DM, Burke TE et al. Secondary cytoreductive surgery for a clinically apparent solitary intra-abdominal recurrence in patients with epithelial ovarian cancer. Proceedings of the American Society of Clinical Oncology 1996; 15: 295 (abstract).
32. Segna RA, Dottino PR, Mandeli JP et al. Secondary cytoreduction for ovarian cancer following cisplatin therapy. Journal of Clinical Oncology 1993; 11: 434-439.
33. Morris M, Gershenson DM, Taylor Wharton J et al. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecologic Oncology 1989; 34: 334-338.
34. Pecorelli S, Sartori E & Santin AD. Follow-up after primary therapy: management of the symptomatic patient. Surgery Gynecologic Oncology 1994; 55S: 138-142.